Autolus Other Current Liab vs Net Receivables Analysis
AUTL Stock | USD 3.84 0.03 0.78% |
Autolus Therapeutics financial indicator trend analysis is way more than just evaluating Autolus Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Autolus Therapeutics is a good investment. Please check the relationship between Autolus Therapeutics Other Current Liab and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.
Other Current Liab vs Net Receivables
Other Current Liab vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Autolus Therapeutics Other Current Liab account and Net Receivables. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Autolus Therapeutics' Other Current Liab and Net Receivables is 0.52. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Autolus Therapeutics, assuming nothing else is changed. The correlation between historical values of Autolus Therapeutics' Other Current Liab and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Autolus Therapeutics are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Other Current Liab i.e., Autolus Therapeutics' Other Current Liab and Net Receivables go up and down completely randomly.
Correlation Coefficient | 0.52 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Other Current Liab
Net Receivables
Most indicators from Autolus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Autolus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.Enterprise Value is expected to rise to about 882.2 M this year, although the value of Selling General Administrative will most likely fall to about 7.2 M.
2021 | 2022 | 2024 (projected) | Depreciation And Amortization | 7.4M | 6.6M | 4.9M | Interest Income | 1.7M | 11.9M | 627K |
Autolus Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Autolus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Autolus Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 254.2M | 294.2M | 405.6M | 490.3M | 375.4M | 279.3M | |
Other Current Liab | 2.3M | 496K | 150K | 40.8M | 44.7M | 2.2M | |
Total Current Liabilities | 21.1M | 33.6M | 28.6M | 46.4M | 44.7M | 24.3M | |
Total Stockholder Equity | 232.6M | 210.0M | 313.3M | 298.7M | 111.5M | 199.4M | |
Net Tangible Assets | 232.6M | 209.9M | 313.3M | 298.7M | 267.5M | 213.2M | |
Retained Earnings | (113.3M) | (379.2M) | (521.3M) | (670.2M) | (878.6M) | (119.0M) | |
Accounts Payable | 2.0M | 2.3M | 431K | 531K | 103K | 1.9M | |
Cash | 217.5M | 153.3M | 310.3M | 382.4M | 239.6M | 206.2M | |
Net Receivables | 13.3M | 29.7M | 26.3M | 29.0M | 24.5M | 18.5M | |
Other Current Assets | 105K | 43.7M | 240K | 203K | 35.7M | 99.8K | |
Total Liab | 21.6M | 84.2M | 92.2M | 191.6M | 263.9M | 20.5M | |
Total Current Assets | 233.0M | 197.0M | 347.0M | 425.8M | 275.3M | 231.8M | |
Intangible Assets | 9.3M | 254K | 158K | 65K | 58.5K | 55.6K | |
Common Stock | 1.3K | 2K | 3K | 4K | 8K | 3.3K | |
Property Plant Equipment | 20.0M | 89.7M | 52.3M | 58.4M | 23.0M | 36.1M | |
Short Long Term Debt Total | 54.2M | 21.0M | 24.3M | 53.0M | 60.9M | 64.0M | |
Other Liab | 601K | 492K | 47.1M | 126.0M | 565.8K | 537.5K | |
Property Plant And Equipment Net | 89.7M | 52.3M | 58.4M | 95.7M | 110.0M | 115.5M | |
Net Debt | (99.1M) | (289.3M) | (358.2M) | (186.6M) | (167.9M) | (176.3M) | |
Non Current Assets Total | 97.3M | 58.6M | 64.5M | 100.1M | 115.1M | 120.8M | |
Cash And Short Term Investments | 217.5M | 153.3M | 310.3M | 382.4M | 239.6M | 228.3M | |
Common Stock Shares Outstanding | 51.6M | 72.1M | 95.0M | 173.9M | 200.0M | 210.0M | |
Liabilities And Stockholders Equity | 294.2M | 405.6M | 490.3M | 375.4M | 431.7M | 312.1M | |
Non Current Liabilities Total | 50.6M | 63.7M | 145.2M | 219.2M | 252.0M | 264.6M | |
Other Stockholder Equity | (15.4M) | 595.1M | 843.2M | 1.0B | 1.0B | (14.6M) | |
Property Plant And Equipment Gross | 20.0M | 89.7M | 75.0M | 86.0M | 124.4M | 19.0M | |
Accumulated Other Comprehensive Income | (10M) | (5.9M) | (8.6M) | (38.9M) | (29.0M) | (10.5M) | |
Net Invested Capital | 210.0M | 313.3M | 298.7M | 111.5M | 128.2M | 249.3M | |
Net Working Capital | 163.4M | 318.4M | 379.4M | 230.6M | 265.1M | 266.4M | |
Inventory | (29.7M) | 10.1M | 14.2M | (24.5M) | (22.1M) | (21.0M) | |
Capital Lease Obligations | 54.2M | 21.0M | 24.3M | 53.0M | 60.9M | 39.3M | |
Short Term Debt | 3.6M | 4.5M | 5.0M | 5.1M | 5.8M | 4.5M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Autolus Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Autolus Stock analysis
When running Autolus Therapeutics' price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Autolus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.21) | Revenue Per Share 0.056 | Quarterly Revenue Growth 6.81 | Return On Assets (0.16) | Return On Equity (0.52) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.